If You Look Ahead of Haleon PLC (HLN), This is What You See

Haleon PLC (NYSE:HLN) is one of the best large cap penny stocks under $10 to buy now. Haleon PLC (NYSE:HLN) reported its Q1 2026 results on April 29. The results showed strong growth in the oral health segment and difficulties in the digestive health, respiratory health, and pain relief segments. But even with that, the management is sticking with its full-year 2026 guidance.

Haleon’s organic revenue 2.2% YoY to £2.86 billion. By geography, the company recorded its strongest organic sales growth of 4% in the Asia Pacific region. The North American segment registered an organic growth of 1%. In the Middle East, where Haleon generates 5% of its sales, the regional conflict had no impact on the business.

The company continued to see stronger growth in its emerging markets compared to developed markets at 4.3% versus 1%.

In terms of product segments, the oral health division recorded the strongest organic growth at 8.3%, followed by therapeutic skin health and other at 3%. The oral health segment sales were driven by double-digit growth in Sensodyne and Parodontax sales.

Looking ahead, the Haleon management reiterated the full-year 2026 organic growth forecast of 3% to 5%. The management also expects the operating profit to grow at a high single-digit rate. On shareholder returns, Haleon allocated £500 million to share repurchases in 2026.

Haleon PLC (NYSE:HLN) is a British multinational company that manufactures consumer health products. It manufactures and sells products for oral health, digestive health, respiratory health, and pain relief. Its brands include Panadol painkiller and Sensodyne toothpaste. The company also provides vitamins and supplements.

READ NEXT: 10 Best Stocks to Buy in a Rising Market According to Wall Street Analysts and Goldman Sachs Gold Stocks: Top 10 Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.